Clinical Trial Update: Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial investigates the combination of cixutumumab and sorafenib in adults with advanced hepatocellular carcinoma. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Cixutumumab (Cixutumumab)
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 1 | Status: COMPLETED